Actavis Says 'Product-Hopping' Ruling Aids Namenda Appeal
A Pennsylvania judge's recent decision to toss a "product-hopping" suit supports Actavis PLC's claim that it didn't violate antitrust law by pulling an older version of Alzheimer's treatment Namenda from the...To view the full article, register now.
Already a subscriber? Click here to view full article